全文获取类型
收费全文 | 72067篇 |
免费 | 7751篇 |
国内免费 | 2710篇 |
专业分类
耳鼻咽喉 | 183篇 |
儿科学 | 620篇 |
妇产科学 | 274篇 |
基础医学 | 3185篇 |
口腔科学 | 1321篇 |
临床医学 | 6189篇 |
内科学 | 7341篇 |
皮肤病学 | 1081篇 |
神经病学 | 2395篇 |
特种医学 | 1038篇 |
外国民族医学 | 7篇 |
外科学 | 2493篇 |
综合类 | 9790篇 |
现状与发展 | 5篇 |
一般理论 | 6篇 |
预防医学 | 5554篇 |
眼科学 | 718篇 |
药学 | 31867篇 |
45篇 | |
中国医学 | 4666篇 |
肿瘤学 | 3750篇 |
出版年
2024年 | 75篇 |
2023年 | 1178篇 |
2022年 | 1435篇 |
2021年 | 2491篇 |
2020年 | 2681篇 |
2019年 | 2674篇 |
2018年 | 2719篇 |
2017年 | 2994篇 |
2016年 | 2838篇 |
2015年 | 2862篇 |
2014年 | 4858篇 |
2013年 | 7993篇 |
2012年 | 4982篇 |
2011年 | 5122篇 |
2010年 | 4027篇 |
2009年 | 3646篇 |
2008年 | 3525篇 |
2007年 | 3507篇 |
2006年 | 3128篇 |
2005年 | 2801篇 |
2004年 | 2298篇 |
2003年 | 2070篇 |
2002年 | 1626篇 |
2001年 | 1549篇 |
2000年 | 1179篇 |
1999年 | 981篇 |
1998年 | 818篇 |
1997年 | 773篇 |
1996年 | 641篇 |
1995年 | 603篇 |
1994年 | 533篇 |
1993年 | 458篇 |
1992年 | 510篇 |
1991年 | 417篇 |
1990年 | 334篇 |
1989年 | 275篇 |
1988年 | 280篇 |
1987年 | 266篇 |
1986年 | 207篇 |
1985年 | 218篇 |
1984年 | 179篇 |
1983年 | 134篇 |
1982年 | 117篇 |
1981年 | 95篇 |
1980年 | 70篇 |
1979年 | 62篇 |
1978年 | 72篇 |
1977年 | 53篇 |
1976年 | 52篇 |
1975年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
1.
目的 基于文本挖掘技术和生物医学数据库对新型冠状病毒肺炎(COVID-19)相关文献进行数据挖掘分析,探究COVID-19及其主要症状发热、咳嗽、呼吸障碍相关基因靶点,筛选潜在有效的化学药和中药。方法 使用GenCLiP 3网站获取COVID-19和其主要症状咳嗽、发热、呼吸障碍共4个关键词的共有靶点,在METASCAPE数据库中对其进行基因本体(GO)和通路富集分析,再利用String数据库和Cytoscape软件构建共有靶点的蛋白质相互作用网络,筛选获得核心基因,运用DGIdb数据库、SymMap数据库针对核心基因进行中西医治疗药物预测。结果 获得COVID-19及其主要症状共有基因靶点28个,其中有IL2、IL1B、CCL2等核心基因16个,使用DGIdb数据库筛选获得与16个关键靶点相互作用的化学药包括沙利度胺、来氟米特、环孢素等28种,中药包括虎杖、黄芪、芦荟等70味。结论 COVID-19及其主要症状的病理机制可能和CD4、KNG1、VEGFA等28个共有基因相关,可能通过介导TNF、IL-17等信号通路参与COVID-19病理过程。潜在有效药物可能通过作用相关靶点通路起到治疗COVID-19的作用。 相似文献
2.
3.
4.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
5.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
6.
《Journal of the American Medical Directors Association》2022,23(3):379-386.e3
ObjectivesPreclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.DesignRandomized double-blind placebo-controlled delayed-start study.Setting and ParticipantPatients with mild to moderate probable AD by NINCDS-ADRDA criteria, stable on acetylcholinesterase inhibitors or memantine (n = 125), were randomized to receive MLC901 (early starters) or placebo (delayed starters) for 6 months, followed by a further 6 months when all patients received MLC901, in a delayed-start design (clinical trial registration: ClinicalTrials.gov, NCT03038035).MethodsThe primary outcome measure was occurrence of serious adverse events (SAEs) at 6 months. Secondary outcomes included the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and other assessment scales.ResultsThere was no significant difference in the risk of SAEs between early and delayed starters at month (M) 6 (22.6% vs 27.0%, risk difference ?4.4%, 90% CI –16.9% to 8.3%). Similarly, there was no significant difference in the risk of adverse events and the occurrence of stroke or vascular events between early and delayed starters throughout the 12-month study period. Early starters did not differ significantly on ADAS-Cog from delayed starters at M6 [mean difference (MD) ?1.0, 95% CI –3.3 to 1.3] and M12 (MD –2.35, 95% CI –5.45 to 0.74) on intention-to-treat analysis. Other cognitive assessment scales did not show significant differences.Conclusions and ImplicationsThis study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD. 相似文献
7.
8.
9.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
10.
在当前国际制药技术出现重大创新和变革、药品研发技术信息化和数字化程度不断发展,以及新型冠状病毒肺炎(COVID-19)疫情大流行的背景下,欧盟委员会为满足未竟临床需求、激励行业创新、增强监管系统应变能力、巩固欧盟药品监管体系国际地位,于2020年底发布了《欧洲药物战略》(Pharmaceutical Strategy for Europe,PSE)。PSE被视为欧洲未来5年卫生政策的“基石”,对欧洲制药领域发展和管理具有重要指导意义。通过对PSE制定背景及发展战略目标、具体举措等内容进行梳理分析,并结合中国COVID-19疫情防控与行业发展、药品科学监管与鼓励创新等实际工作提出政策建议。 相似文献